1. Home
  2. NCRA vs EDSA Comparison

NCRA vs EDSA Comparison

Compare NCRA & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

N/A

Current Price

$0.82

Market Cap

13.2M

ML Signal

N/A

Logo Edesa Biotech Inc.

EDSA

Edesa Biotech Inc.

HOLD

Current Price

$1.43

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
EDSA
Founded
2002
2015
Country
Taiwan
Canada
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
12.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
EDSA
Price
$0.82
$1.43
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.00
AVG Volume (30 Days)
75.4K
34.5K
Earning Date
04-01-2026
12-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$1.28
52 Week High
$2.40
$4.49

Technical Indicators

Market Signals
Indicator
NCRA
EDSA
Relative Strength Index (RSI) 38.12 27.37
Support Level $0.80 $1.27
Resistance Level $0.95 $1.50
Average True Range (ATR) 0.14 0.08
MACD -0.01 -0.02
Stochastic Oscillator 3.13 9.09

Price Performance

Historical Comparison
NCRA
EDSA

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

Share on Social Networks: